7th Conference "CePT - a platform for the development of innovative biomedicine 2018"

Oncology: the company will present the research results at the AACR

A big appetite for ambitious novelties

An innovative drug for breast cancer?

Changes in Helix Immuno-Oncology.

Helix Immuno-Oncology to present its research results in Chicago

The FDA accelerates work on a clinical trial of L-DOS47

Poland must seize the opportunity in the field of biotechnology.

The R&D results concerning the V-DOS47 molecule published in “Frontiers in Immunology”

Research results of V-DOS47 in “Frontiers in Immunology”

Helix Immuno-Oncology conducts research on new cancer treatment strategies

The Polish company is working on a technology that may become a breakthrough in the treatment of solid tumors. Among others lung, breast or pancreatic cancer

Tumour Defence Breaker DOS-47 technology breaks the cancer defence barriers

Effective therapy for solid tumors ... soon available in Poland?

The Polish biotechnology company presented the clinical trial results of the L-DOS47 molecule in non-small cell lung cancer

Helix Immuno-Oncology: DOS47 (Tumour Defence Breaker)

More effective fight against cancer

Expanding access to immunotherapy of cancers

Innovative anti-cancer therapy tested in Poland

Tumor Defence Breaker – a breakthrough in the treatment of solid tumors?